Multiple Sclerosis Clinical Trial
Official title:
Real-world Patient Profile and Treatment Persistence of Ocrelizumab in Multiple Sclerosis: A Retrospective Analysis in Latin America
It has been almost 25 years since the publication of the pivotal trial results for the first
disease-modifying therapy (DMT) for RRMS. Currently disease modifying therapies (DMTs) for MS
approved by the European Medicine Agency (EMA) and Food and Drug Administration (FDA) include
interferon beta (IFNβ) 1-a and 1-b, glatiramer acetate (GA), mitoxantrone, natalizumab,
fingolimod, teriflunomide, dimethyl fumarate, alemtuzumab, daclizumab and ocrelizumab.
Despite evidence about ocrelizumab exist in many patients from eurpe and North America,
scarce real world evidence exists about epidemiolofcal aspects of patients that used
ocrelizumab in Latin America.
The aim of this study is therefore to evaluate patient profiles and persistence to treatment
during follow up in a retrospective study of patients who had been prescribed ocrelizumab for
the treatment of MS in Latin America (LATAM). The investigators will include MS patients that
received ocrelizumab in Latin America and describe epidemiological aspects and persistence to
treatment during the last 12 months.
Multiple sclerosis is a chronic inflammatory disease of the CNS that leads to focal plaques
of primary demyelination and diffuse neurodegeneration in the grey and white matter of the
brain and spinal cord 1. In most patients, the disease starts with a relapsing-remitting
course (RRMS), which is followed several years by a secondary progressive phase (SPMS).
Patients with primary progressive disease (PPMS) miss the relapsing and remitting stage and
start with uninterrupted progression from disease onset 1-3.
It has been almost 25 years since the publication of the pivotal trial results for the first
disease-modifying therapy (DMT) for RRMS 4. Currently disease modifying therapies (DMTs) for
MS approved by the European Medicine Agency (EMA) and Food and Drug Administration (FDA)
include interferon beta (IFNβ) 1-a and 1-b, glatiramer acetate (GA), mitoxantrone,
natalizumab, fingolimod, teriflunomide, dimethyl fumarate, alemtuzumab, daclizumab and
ocrelizumab 5-7.
Ocrelizumab was approved in March 2017 for the treatment of relapsing or primary progressive
MS 8. A phase II trial established 600 mg intravenously every 6 months as the preferred
dosing schedule. Two phase III trials evaluated the efficacy of ocrelizumab in patients with
relapsing remitting MS, and individual and pooled analysis demonstrated a significant
reduction in annualized relapse rate (P < 0.001 pooled), disability progression at 12 weeks (
P < 0.001 pooled), and gadolinium-enhancing lesions on magnetic resonance imaging (MRI; P <
0.001) 8. Patients with PPMS were evaluated in a third phase III trial, which showed a
significant decrease in disease progression at 12 weeks ( P = 0.03) and volume of T2-weighted
lesions on MRI ( P < 0.001) 8. As with other monoclonal antibodies, adverse effects seen with
ocrelizumab were primarily infusion-related reactions and infection8. Despite much
information exists about efficacy and safety of ocrelizumab in phase III clinical trials,
scarce evidence exists regarding real world patients profile and safety.
The aim of this study is therefore to evaluate patient profiles and persistence to treatment
during follow up in a retrospective study of patients who had been prescribed ocrelizumab for
the treatment of MS in Latin America (LATAM)
Methods
Verbal/written consent from patient only if any site's Ethic Committee requests it.
Centers involved in the study will be from Mexico, Chile, Argentina Number of centers &
patients Two centers in Argentina, two centers in Chile, and two centers in Mexico. Total: 6
centers and Approx 80 patients.
Study overview Patients that accept to participate and fulfill all inclusion criteria and
none exclusion criteria will be included. All information will be extracted from the medical
charts Data Source Information related to the study population will be extracted from the
patient medical chart review (secondary data use) and will cover a period up to protocol
regulatory approval. Patient identity will be coded and anonymized in the study data base so
only each investigator will know the identity of each patient. Local legislation regarding
patient data protection will be followed strictly in this study. All study data will be
entered in a predefined electronic Case Report Form (CRF).
This is an NIS involving the use of secondary data and the reporting of adverse reactions in
the form of ICSRs is not required. The study will not extract safety information.
Storage and data analysis
Once the patient is identified and consented to participate (if needed based on local
regulatory aspects), data from patient's chart will be transferred into the specifically
designed platform. The platform on which variables will be transferred, will be on a web
platform with restricted access by user and password specific to each researcher. When
sharing the data, it will be anonymized and only data related to the demographics and clinic
will be accessible, and patient data such as name, surname and ID will not be visible to
analysts if it is loaded.
Data protection
The regulatory requirements and protection of personal data must be completed according to
the regulations corresponding to each participant.
Each researcher in the study should explain in detail to each potential participant the
record consists. Every patient who wishes to participate in the project must consent,
according to each regulation, authorizing that their information, codified and anonymized, be
shared with other records for analysis and communication.
An institutional ethics committee must approve the registration or declare that it is exempt
from the need for approval as well as its informed consent (IC).
The data will be uploaded by the physician of each participating center. The different
variables will be obtained from the daily clinical practice of each professional.
Patient Confidentiality As mentioned in the previous point, the patient's name, address, date
of birth, ID or telephone number will only be left in the personal registry and at the moment
of sharing the registration to the central registry will not be entered. The records will
then be identified by a unique code generated by the initials of the IP and the registration
number of that patient.
Each registry should include baseline clinical and demographic data as well as the study
project data.
At all times, the protection of the patient's identity and data will be observed in
accordance with the legal regulations in force national law of protection of personal data
25.326 (Habeas Data), in accordance with the international legislation on registration of
diseases and protection of personal data and private, according to the 18th World Medical
Assembly of Helsinki (1964) when applicable. The right to non-participation in the study will
be respected always without this implying in any case any type of discrimination,
differential treatment or mistreatment towards the patient.
This is a retrospective observational study, which does not plan any type of intervention or
differential treatment in patients included or excluded.
Statistical analysis plan This is descriptive study and sample size is not based on
statistical considerations. A descriptive analysis is the main objective of the study
regarding demographic, clinical aspects, disease activity and persistence to treatment of
patients that received ocrelizumab to treat their MS disease.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05528666 -
Risk Perception in Multiple Sclerosis
|
||
Completed |
NCT03608527 -
Adaptive Plasticity Following Rehabilitation in Multiple Sclerosis
|
N/A | |
Recruiting |
NCT05532943 -
Evaluate the Safety and Efficacy of Allogeneic Umbilical Cord Mesenchymal Stem Cells in Patients With Multiple Sclerosis
|
Phase 1/Phase 2 | |
Completed |
NCT02486640 -
Evaluation of Potential Predictors of Adherence by Investigating a Representative Cohort of Multiple Sclerosis (MS) Patients in Germany Treated With Betaferon
|
||
Completed |
NCT01324232 -
Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis
|
Phase 2 | |
Completed |
NCT04546698 -
5-HT7 Receptor Implication in Inflammatory Mechanisms in Multiple Sclerosis
|
||
Active, not recruiting |
NCT04380220 -
Coagulation/Complement Activation and Cerebral Hypoperfusion in Relapsing-remitting Multiple Sclerosis
|
||
Completed |
NCT02835677 -
Integrating Caregiver Support Into MS Care
|
N/A | |
Completed |
NCT03686826 -
Feasibility and Reliability of Multimodal Evoked Potentials
|
||
Recruiting |
NCT05964829 -
Impact of the Cionic Neural Sleeve on Mobility in Multiple Sclerosis
|
N/A | |
Withdrawn |
NCT06021561 -
Orofacial Pain in Multiple Sclerosis
|
||
Completed |
NCT03653585 -
Cortical Lesions in Patients With Multiple Sclerosis
|
||
Recruiting |
NCT04798651 -
Pathogenicity of B and CD4 T Cell Subsets in Multiple Sclerosis
|
N/A | |
Active, not recruiting |
NCT05054140 -
Study to Evaluate Efficacy, Safety, and Tolerability of IMU-838 in Patients With Progressive Multiple Sclerosis
|
Phase 2 | |
Completed |
NCT05447143 -
Effect of Home Exercise Program on Various Parameters in Patients With Multiple Sclerosis
|
N/A | |
Recruiting |
NCT06195644 -
Effect of Galvanic Vestibular Stimulation on Cortical Excitability and Hand Dexterity in Multiple Sclerosis Patients
|
Phase 1 | |
Completed |
NCT04147052 -
iSLEEPms: An Internet-Delivered Intervention for Sleep Disturbance in Multiple Sclerosis
|
N/A | |
Completed |
NCT03591809 -
Combined Exercise Training in Patients With Multiple Sclerosis
|
N/A | |
Completed |
NCT03594357 -
Cognitive Functions in Patients With Multiple Sclerosis
|
||
Completed |
NCT02845635 -
MS Mosaic: A Longitudinal Research Study on Multiple Sclerosis
|